世界の迷走神経刺激（VNS）市場

出版：Market Research Future（マーケットリサーチフューチャー）　出版年月：2021年08月

世界の迷走神経刺激（VNS）市場：製品（埋め込み型VNSデバイス、外部VNSデバイス）、用途別（うつ病、てんかん、その他）、エンドユーザー別（病院、外来手術センター）、地域（北米、ヨーロッパ、アジア太平洋、RoW）-2027年までの予測

Global Vagal Nerve Stimulation (VNS) Market: Information by Products (Implantable VNS Devices, External VNS Devices), By Application (Depression, Epilepsy, Others), By End User (Hospitals, Ambulatory Surgical Centers), and Region(North America, Europe, Asia-Pacific, and Rest of the World)—Forecast till 2027

レポート目次　　見積ご依頼・お問合せ　　ご購入案内

Global Vagal Nerve Stimulation (VNS) Market—Forecast till 2027

Vagal Nerve Stimulation Market Overview

The Vagal Nerve Stimulation (VNS) market is anticipated to surpass USD 1,076.83 million by 2027 with a significant CAGR of 10.30%. Vagus nerve stimulation includes the utilization of a gadget to invigorate the vagus nerve with electrical driving forces. An implantable vagus nerve trigger is presently FDA-endorsed to treat epilepsy and melancholy. The outside Vagal Nerve Stimulation (VNS) gadgets depend totally on electrical signs that can be going through the skin and muscles of the neck without influencing the tissue it is going through. This method should be sufficiently exact to manage and get to explicit action of the nerve. Development in innovation and the presentation of new outside VNS gadgets are relied upon to fuel the development of the vagal nerve trigger market.

The worldwide Vagal Nerve Stimulation (VNS) market is fundamentally determined by the expanding pervasiveness of neurological problems and rising speculation of biotechnology and drug ventures in R&D. In any case, factors, for example, the greater expense of the vagal nerve stimulation treatment strategy are relied upon to confine the market’s development during the estimate time frame. Besides, the expanding vital consolidations and acquisitions will set out open doors for market players. However, the higher cost of vagal nerve stimulation treatment procedure is set to hamper the global market growth during the review period.

Segment Overview
The global Vagal Nerve Stimulation (VNS) market has been classified into products, applications, and end-user.
By-Products type the global market is divided into Implantable VNS Devices and External VNS Devices.
Based on Application the market is categorized into depression, epilepsy, and others.
In terms of the end-user segment, the global market is classified into hospitals, ambulatory surgical centers, and others.
Regional Analysis
The global vagal nerve stimulation (VNS) market, based on region, has been divided into North America, Europe, Asia-Pacific, and the Rest of the World.
North America is expected to command the global vagal stimulation (VNS) market with a healthy CAGR of 9.87% during the review period. the regional market is attributed to the advanced technology, rising prevalence of neurological disorders, increasing healthcare expenditure, and supportive government support for research & development. Europe contributes the second position in the global vagal nerve stimulation market owing to the increasing government support and funding for research & development.
The Asia-Pacific vagal nerve stimulation market is expected to register a significant CAGR of 10.69% during the study period. The regional market is attributed to the existence of rapidly developing healthcare technology, a large patient population, and increased healthcare expenditure. The Rest of the World’s vagal nerve stimulation market is categorized into two major regions, namely the Middle East & Africa and Latin America.
Key Competitors
The major players of the global vagal nerve stimulation market are LivaNova, PLC (UK), ReShape Lifesciences Inc (US), ElectroCore Medical LLC (US), Boston Scientific Corporation (US), NeuroMetrix, Inc. (US), ImThera Medical, Inc. (US), Inspire Medical Systems, Inc (US), Parasym Ltd (UK), and Innovative Health Solutions, Inc. (the US).

COVID 19 Impacts
We are continuously tracking the impact of the COVID-19 pandemic on various industries and verticals within all domains. Our research reports include the same and help you understand the drop and rise, owing to the impact of COVID-19 on the industries. Also, we help you to identify the gap between the demand and supply of your interested market. Moreover, the report helps you with the analysis, amended government regulations, and many other useful insights.

目次

TABLE OF CONTENTS

1 EXECUTIVE SUMMARY

1.1 MARKET ATTRACTIVENESS ANALYSIS

1.1.1 GLOBAL VAGAL NERVE STIMULATION MARKET, BY PRODUCTS, 2019

1.1.2 GLOBAL VAGAL NERVE STIMULATION MARKET, BY APPLICATION, 2019

1.1.3 GLOBAL VAGAL NERVE STIMULATION MARKET, BY END USER

1.1.4 GLOBAL VAGAL NERVE STIMULATION MARKET, BY REGION

2 MARKET INTRODUCTION

2.1 DEFINITION

2.2 SCOPE OF THE STUDY

2.3 MARKET STRUCTURE

3 RESEARCH METHODOLOGY

3.1 RESEARCH PROCESS

3.2 PRIMARY RESEARCH

3.3 SECONDARY RESEARCH

3.4 MARKET SIZE ESTIMATION

3.5 TOP DOWN & BOTTOM-UP APPROACH

3.6 FORECAST MODEL

3.7 LIST OF ASSUMPTIONS& LIMITATIONS

4 MARKET DYNAMICS

4.1 INTRODUCTION

4.2 DRIVERS

4.2.1 INCREASING PREVALENCE OF NEUROLOGICAL DISORDERS

4.2.2 INCREASING INVESTMENT OF BIOTECHNOLOGY AND PHARMACEUTICAL INDUSTRIES IN R&D

4.2.3 DRIVERS IMPACT ANALYSIS

4.3 RESTRAINTS

4.3.1 HIGHER COST OF VAGAL NERVE STIMULATIO TREATMENT PROCEDURE

4.3.2 RESTRAINTS IMPACT ANALYSIS

4.4 OPPORTUNITIES

4.4.1 INCREASING STRATEGIC MERGERS AND ACQUISITIONS

4.5 IMPACT OF COVID-19 ON THE GLOBAL VAGAL NERVE STIMULATION MARKET

4.5.1 IMPACT ON SUPPLY CHAIN

4.5.2 IMPACT ON PRODUCTION

4.5.3 IMPACT ON PRICING

5 MARKET FACTOR ANALYSIS

5.1 SUPPLY/VALUE CHAIN ANALYSIS

5.1.1 R&D

5.1.2 MANUFACTURING

5.1.3 DISTRIBUTION & SALES

5.1.4 POST-SALES MONITORING

5.2 PORTER’S FIVE FORCES MODEL

5.2.1 THREAT OF NEW ENTRANTS

5.2.2 BARGAINING POWER OF SUPPLIERS

5.2.3 BARGAINING POWER OF BUYERS

5.2.4 THREAT OF SUBSTITUTES

5.2.5 INTENSITY OF RIVALRY

5.3 GLOBAL VNS DEVICE NEWLY IMPLANTED & RE-IMPLANTED BY VOLUME

5.4 EUROPE VNS DEVICE NEWLY IMPLANTED & RE-IMPLANTED BY VOLUME

5.5 US VNS DEVICE NEWLY IMPLANTED & RE-IMPLANTED BY VOLUME

5.6 VNS DEVICE IMPLEMENTED PATIENTS, BY COUNTRY, 2019

6 GLOBAL VAGAL NERVE STIMULATION MARKET, BY PRODUCTS

6.1 OVERVIEW

6.2 IMPLANTABLE VNS DEVICES

6.3 EXTERNAL VNS DEVICES

7 GLOBAL VAGAL NERVE STIMULATION MARKET, BY APPLICATION

7.1 OVERVIEW

7.2 DEPRESSION

7.3 EPILEPSY

7.4 OTHERS

8 GLOBAL VAGAL NERVE STIMULATION MARKET, BY END USER

8.1 OVERVIEW

8.2 HOSPITALS

8.3 AMBULATORY SURGICAL CENTERS

8.4 OTHERS

9 GLOBAL VAGAL NERVE STIMULATION MARKET, BY REGION

9.1 OVERVIEW

9.2 NORTH AMERICA

9.2.1 US

9.2.2 CANADA.

9.3 EUROPE

9.3.1 GERMANY

9.3.2 FRANCE.

9.3.3 UK

9.3.4 ITALY

9.3.5 SPAIN.

9.3.6 REST OF EUROPE.

9.4 ASIA-PACIFIC

9.4.1 CHINA

9.4.2 INDIA.

9.4.3 JAPAN.

9.4.4 AUSTRALIA.

9.4.5 SOUTH KOREA.

9.4.6 REST OF ASIA-PACIFIC.

9.5 REST OF THE WORLD

9.5.1 MIDDLE EAST

9.5.2 AFRICA.

9.5.3 LATIN AMERICA

10 COMPETITIVE LANDSCAPE

10.1 COMPETITIVE OVERVIEW

10.2 GLOBAL VAGAL NERVE STIMULATION MARKET: COMPANY SHARE ANALYSIS

10.3 COMPETITIVE BENCHMARKING

10.4 MAJOR GROWTH STRATEGY IN THE GLOBAL VAGAL NERVE STIMULATION MARKET

10.5 THE LEADING PLAYER IN TERMS OF NUMBER OF DEVELOPMENTS IN GLOBAL VAGAL NERVE STIMULATION MARKET

10.6 KEY DEVELOPMENTS & GROWTH STRATEGIES

10.6.1 NEW PRODUCTS LAUNCH/SERVICE DEPLOYMENT

10.6.2 MERGER & ACQUISITION

10.6.3 COLLABORATION

10.7 MAJOR PLAYERS FINANCIAL MATRIX & MARKET RATIO

10.7.1 SALES & OPERATING INCOME

10.7.2 R&D EXPENDITURE

11 COMPANY PROFILES

11.1 LIVANOVA PLC

11.1.1 COMPANY OVERVIEW

11.1.2 FINANCIAL OVERVIEW

11.1.3 PRODUCTS OFFERED

11.1.4 KEY DEVELOPMENTS

11.1.5 SWOT ANALYSIS

11.1.6 KEY STRATEGIES

11.2 RESHAPE LIFESCIENCES, INC.

11.2.1 COMPANY OVERVIEW

11.2.2 FINANCIAL OVERVIEW

11.2.3 PRODUCTS OFFERED

11.2.4 KEY DEVELOPMENTS

11.2.5 SWOT ANALYSIS

11.2.6 KEY STRATEGIES

11.3 ELECTROCORE MEDICAL LLC

11.3.1 COMPANY OVERVIEW

11.3.2 FINANCIAL OVERVIEW

11.3.3 PRODUCTS OFFERED

11.3.4 KEY DEVELOPMENTS

11.3.5 SWOT ANALYSIS

11.3.6 KEY STRATEGIES

11.4 BOSTON SCIENTIFIC CORPORATION

11.4.1 COMPANY OVERVIEW

11.4.2 FINANCIAL OVERVIEW

11.4.3 PRODUCTS OFFERED

11.4.4 KEY DEVELOPMENTS

11.4.5 SWOT ANALYSIS

11.4.6 KEY STRATEGIES

11.5 NEUROMETRIX, INC.

11.5.1 COMPANY OVERVIEW

11.5.2 FINANCIAL OVERVIEW

11.5.3 PRODUCTS OFFERED

11.5.4 KEY DEVELOPMENTS

11.5.5 SWOT ANALYSIS

11.5.6 KEY STRATEGIES

11.6 IMTHERA MEDICAL INC.

11.6.1 COMPANY OVERVIEW

11.6.2 FINANCIAL OVERVIEW

11.6.3 PRODUCTS OFFERED

11.6.4 SWOT ANALYSIS

11.6.5 KEY STRATEGIES

11.7 INSPIRE MEDICAL SYSTEMS, INC.

11.7.1 COMPANY OVERVIEW

11.7.2 FINANCIAL OVERVIEW

11.7.3 PRODUCTS OFFERED

11.7.4 KEY DEVELOPMENTS

11.7.5 SWOT ANALYSIS

11.7.6 KEY STRATEGIES

11.8 PARASYM LTD

11.8.1 COMPANY OVERVIEW

11.8.2 FINANCIAL OVERVIEW

11.8.3 PRODUCTS OFFERED

11.8.4 KEY DEVELOPMENTS

11.8.5 SWOT ANALYSIS

11.8.6 KEY STRATEGIES

11.9 INNOVATIVE HEALTH SOLUTIONS INC.

11.9.1 COMPANY OVERVIEW

11.9.2 FINANCIAL OVERVIEW

11.9.3 PRODUCTS OFFERED

11.9.4 KEY DEVELOPMENTS

11.9.5 SWOT ANALYSIS

11.9.6 KEY STRATEGIES

12 APPENDIX

12.1 REFERENCES

12.2 RELATED REPORTS
LIST OF TABLES

TABLE 1 LIST OF ASSUMPTIONS& LIMITATIONS

TABLE 2 GLOBAL VNS DEVICE NEWLY IMPLANTED & RE-IMPLANTED BY VOLUME, 2016–2020 (UNITS)

TABLE 3 EUROPE VNS DEVICE NEWLY IMPLANTED & RE-IMPLANTED BY VOLUME, 2016–2020 (UNITS)

TABLE 4 US VNS DEVICE NEWLY IMPLANTED & RE-IMPLANTED BY VOLUME, 2016–2020 (UNITS)

TABLE 5 VNS DEVICE IMPLEMENTED PATIENTS, BY COUNTRY, 2019

TABLE 6 GLOBAL VAGAL NERVE STIMULATION MARKET, BY PRODUCTS, 2017–2027 (USD MILLION)

TABLE 7 GLOBAL VAGAL NERVE STIMULATION MARKET FOR IMPLANTABLE VNS DEVICES, BY REGION, 2017–2027 (USD MILLION)

TABLE 8 GLOBAL VAGAL NERVE STIMULATION MARKET FOR EXTERNAL VNS DEVICES, BY REGION, 2017–2027 (USD MILLION)

TABLE 9 GLOBAL VAGAL NERVE STIMULATION MARKET, BY APPLICATION, 2017–2027 (USD MILLION)

TABLE 10 GLOBAL VAGAL NERVE STIMULATION MARKET, BY DEPRESSION, BY REGION, 2017–2027 (USD MILLION)

TABLE 11 GLOBAL VAGAL NERVE STIMULATION MARKET, BY EPILEPSY, BY REGION, 2017–2027 (USD MILLION)

TABLE 12 GLOBAL VAGAL NERVE STIMULATION MARKET, BY OTHERS, BY REGION, 2017–2027 (USD MILLION)

TABLE 13 GLOBAL VAGAL NERVE STIMULATION MARKET, BY END USER, 2017–2027 (USD MILLION)

TABLE 14 GLOBAL VAGAL NERVE STIMULATION MARKET, BY HOSPITALS, BY REGION, 2017–2027 (USD MILLION)

TABLE 15 GLOBAL VAGAL NERVE STIMULATION MARKET, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2017–2027 (USD MILLION)

TABLE 16 GLOBAL VAGAL NERVE STIMULATION MARKET, BY OTHERS, BY REGION, 2017–2027 (USD MILLION)

TABLE 17 GLOBAL VAGAL NERVE STIMULATION MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 18 NORTH AMERICA: VAGAL NERVE STIMULATION MARKET, BY COUNTRY, 2017-2027 (USD MILLION)

TABLE 19 NORTH AMERICA: VAGAL NERVE STIMULATION MARKET, BY PRODUCTS, 2017-2027 (USD MILLION)

TABLE 20 NORTH AMERICA: VAGAL NERVE STIMULATION MARKET, BYAPPLICATION, 2017-2027 (USD MILLION)

TABLE 21 NORTH AMERICA: VAGAL NERVE STIMULATION MARKET, BY END USER, 2017-2027 (USD MILLION)

TABLE 22 US: VAGAL NERVE STIMULATION MARKET, BY PRODUCTS, 2017-2027 (USD MILLION)

TABLE 23 US: VAGAL NERVE STIMULATION MARKET, BYAPPLICATION, 2017-2027 (USD MILLION)

TABLE 24 US: VAGAL NERVE STIMULATION MARKET, BY END USER, 2017-2027 (USD MILLION)

TABLE 25 CANADA: VAGAL NERVE STIMULATION MARKET, BY PRODUCTS, 2017-2027 (USD MILLION)

TABLE 26 CANADA: VAGAL NERVE STIMULATION MARKET, BYAPPLICATION, 2017-2027 (USD MILLION)

TABLE 27 CANADA: VAGAL NERVE STIMULATION MARKET, BY END USER, 2017-2027 (USD MILLION)

TABLE 28 EUROPE: VAGAL NERVE STIMULATION MARKET, BY COUNTRY, 2017-2027 (USD MILLION)

TABLE 29 EUROPE: VAGAL NERVE STIMULATION MARKET, BY PRODUCTS, 2017-2027 (USD MILLION)

TABLE 30 EUROPE: VAGAL NERVE STIMULATION MARKET, BYAPPLICATION, 2017-2027 (USD MILLION)

TABLE 31 EUROPE: VAGAL NERVE STIMULATION MARKET, BY END USER, 2017-2027 (USD MILLION)

TABLE 32 GERMANY: VAGAL NERVE STIMULATION MARKET, BY PRODUCTS, 2017-2027 (USD MILLION)

TABLE 33 GERMANY: VAGAL NERVE STIMULATION MARKET, BYAPPLICATION, 2017-2027 (USD MILLION)

TABLE 34 GERMANY: VAGAL NERVE STIMULATION MARKET, BY END USER, 2017-2027 (USD MILLION)

TABLE 35 FRANCE: VAGAL NERVE STIMULATION MARKET, BY PRODUCTS, 2017-2027 (USD MILLION)

TABLE 36 FRANCE: VAGAL NERVE STIMULATION MARKET, BYAPPLICATION, 2017-2027 (USD MILLION)

TABLE 37 FRANCE: VAGAL NERVE STIMULATION MARKET, BY END USER, 2017-2027 (USD MILLION)

TABLE 38 UK: VAGAL NERVE STIMULATION MARKET, BY PRODUCTS, 2017-2027 (USD MILLION)

TABLE 39 UK: VAGAL NERVE STIMULATION MARKET, BYAPPLICATION, 2017-2027 (USD MILLION)

TABLE 40 UK: VAGAL NERVE STIMULATION MARKET, BY END USER, 2017-2027 (USD MILLION)

TABLE 41 ITALY: VAGAL NERVE STIMULATION MARKET, BY PRODUCTS, 2017-2027 (USD MILLION)

TABLE 42 ITALY: VAGAL NERVE STIMULATION MARKET, BYAPPLICATION, 2017-2027 (USD MILLION)

TABLE 43 ITALY: VAGAL NERVE STIMULATION MARKET, BY END USER, 2017-2027 (USD MILLION)

TABLE 44 SPAIN: VAGAL NERVE STIMULATION MARKET, BY PRODUCTS, 2017-2027 (USD MILLION)

TABLE 45 SPAIN: VAGAL NERVE STIMULATION MARKET, BYAPPLICATION, 2017-2027 (USD MILLION)

TABLE 46 SPAIN: VAGAL NERVE STIMULATION MARKET, BY END USER, 2017-2027 (USD MILLION)

TABLE 47 REST OF EUROPE: VAGAL NERVE STIMULATION MARKET, BY PRODUCTS, 2017-2027 (USD MILLION)

TABLE 48 REST OF EUROPE: VAGAL NERVE STIMULATION MARKET, BYAPPLICATION, 2017-2027 (USD MILLION)

TABLE 49 REST OF EUROPE: VAGAL NERVE STIMULATION MARKET, BY END USER, 2017-2027 (USD MILLION)

TABLE 50 ASIA-PACIFIC: VAGAL NERVE STIMULATION MARKET, BY COUNTRY, 2017-2027 (USD MILLION)

TABLE 51 ASIA-PACIFIC: VAGAL NERVE STIMULATION MARKET, BY PRODUCTS, 2017-2027 (USD MILLION)

TABLE 52 ASIA-PACIFIC: VAGAL NERVE STIMULATION MARKET, BYAPPLICATION, 2017-2027 (USD MILLION)

TABLE 53 ASIA-PACIFIC: VAGAL NERVE STIMULATION MARKET, BY END USER, 2017-2027 (USD MILLION)

TABLE 54 CHINA: VAGAL NERVE STIMULATION MARKET, BY PRODUCTS, 2017-2027 (USD MILLION)

TABLE 55 CHINA: VAGAL NERVE STIMULATION MARKET, BYAPPLICATION, 2017-2027 (USD MILLION)

TABLE 56 CHINA: VAGAL NERVE STIMULATION MARKET, BY END USER, 2017-2027 (USD MILLION)

TABLE 57 INDIA: VAGAL NERVE STIMULATION MARKET, BY PRODUCTS, 2017-2027 (USD MILLION)

TABLE 58 INDIA: VAGAL NERVE STIMULATION MARKET, BYAPPLICATION, 2017-2027 (USD MILLION)

TABLE 59 INDIA: VAGAL NERVE STIMULATION MARKET, BY END USER, 2017-2027 (USD MILLION)

TABLE 60 JAPAN: VAGAL NERVE STIMULATION MARKET, BY PRODUCTS, 2017-2027 (USD MILLION)

TABLE 61 JAPAN: VAGAL NERVE STIMULATION MARKET, BYAPPLICATION, 2017-2027 (USD MILLION)

TABLE 62 JAPAN: VAGAL NERVE STIMULATION MARKET, BY END USER, 2017-2027 (USD MILLION)

TABLE 63 AUSTRALIA: VAGAL NERVE STIMULATION MARKET, BY PRODUCTS, 2017-2027 (USD MILLION)

TABLE 64 AUSTRALIA: VAGAL NERVE STIMULATION MARKET, BYAPPLICATION, 2017-2027 (USD MILLION)

TABLE 65 AUSTRALIA: VAGAL NERVE STIMULATION MARKET, BY END USER, 2017-2027 (USD MILLION)

TABLE 66 SOUTH KOREA: VAGAL NERVE STIMULATION MARKET, BY PRODUCTS, 2017-2027 (USD MILLION)

TABLE 67 SOUTH KOREA: VAGAL NERVE STIMULATION MARKET, BYAPPLICATION, 2017-2027 (USD MILLION)

TABLE 68 SOUTH KOREA: VAGAL NERVE STIMULATION MARKET, BY END USER, 2017-2027 (USD MILLION)

TABLE 69 REST OF ASIA-PACIFIC: VAGAL NERVE STIMULATION MARKET, BY PRODUCTS, 2017-2027 (USD MILLION)

TABLE 70 REST OF ASIA-PACIFIC: VAGAL NERVE STIMULATION MARKET, BYAPPLICATION, 2017-2027 (USD MILLION)

TABLE 71 REST OF ASIA-PACIFIC: VAGAL NERVE STIMULATION MARKET, BY END USER, 2017-2027 (USD MILLION)

TABLE 72 REST OF THE WORLD: VAGAL NERVE STIMULATION MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 73 REST OF THE WORLD: VAGAL NERVE STIMULATION MARKET, BY PRODUCTS, 2017-2027 (USD MILLION)

TABLE 74 REST OF THE WORLD: VAGAL NERVE STIMULATION MARKET, BYAPPLICATION, 2017-2027 (USD MILLION)

TABLE 75 REST OF THE WORLD: VAGAL NERVE STIMULATION MARKET, BY END USER, 2017-2027 (USD MILLION)

TABLE 76 MIDDLE EAST: VAGAL NERVE STIMULATION MARKET, BY PRODUCTS, 2017-2027 (USD MILLION)

TABLE 77 MIDDLE EAST: VAGAL NERVE STIMULATION MARKET, BYAPPLICATION, 2017-2027 (USD MILLION)

TABLE 78 MIDDLE EAST: VAGAL NERVE STIMULATION MARKET, BY END USER, 2017-2027 (USD MILLION)

TABLE 79 AFRICA: VAGAL NERVE STIMULATION MARKET, BY PRODUCTS, 2017-2027 (USD MILLION)

TABLE 80 AFRICA: VAGAL NERVE STIMULATION MARKET, BYAPPLICATION, 2017-2027 (USD MILLION)

TABLE 81 AFRICA: VAGAL NERVE STIMULATION MARKET, BY END USER, 2017-2027 (USD MILLION)

TABLE 82 LATIN AMERICA: VAGAL NERVE STIMULATION MARKET, BY PRODUCTS, 2017-2027 (USD MILLION)

TABLE 83 LATIN AMERICA: VAGAL NERVE STIMULATION MARKET, BYAPPLICATION, 2017-2027 (USD MILLION)

TABLE 84 LATIN AMERICA: VAGAL NERVE STIMULATION MARKET, BY END USER, 2017-2027 (USD MILLION)

TABLE 85 THE MOST ACTIVE PLAYER IN THE GLOBAL VAGAL NERVE STIMULATION MARKET

TABLE 86 NEW PRODUCTS LAUNCH/SERVICE DEPLOYMENT

TABLE 87 MERGER & ACQUISITION

TABLE 88 COLLABORATION

TABLE 89 LIVANOVA PLC: PRODUCTS OFFERED

TABLE 90 LIVANOVA PLC: KEY DEVELOPMENTS

TABLE 91 RESHAPE LIFESCIENCES, INC: PRODUCTS OFFERED

TABLE 92 RESHAPE LIFESCIENCES, INC: KEY DEVELOPMENTS

TABLE 93 ELECTROCORE, INC: PRODUCTS OFFERED

TABLE 94 ELECTROCORE, INC: KEY DEVELOPMENTS

TABLE 95 BOSTON SCIENTIFIC CORPORATION: PRODUCTS OFFERED

TABLE 96 BOSTON SCIENTIFIC CORPORATION: KEY DEVELOPMENTS

TABLE 97 NEUROMETRIX INC.: PRODUCTS OFFERED

TABLE 98 NEUROMETRIX INC.: KEY DEVELOPMENTS

TABLE 99 IMTHERA MEDICAL INC.: PRODUCTS OFFERED

TABLE 100 INSPIRE MEDICAL SYSTEMS, INC: PRODUCTS OFFERED

TABLE 101 INSPIRE MEDICAL SYSTEMS, INC.: KEY DEVELOPMENTS

TABLE 102 PARASYM LTD: PRODUCTS OFFERED

TABLE 103 INNOVATIVE HEALTH SOLUTIONS INC.: PRODUCTS OFFERED

LIST OF FIGURES

FIGURE 1 MARKET SYNOPSIS

FIGURE 2 MARKET ATTRACTIVENESS ANALYSIS: GLOBAL VAGAL NERVE STIMULATION MARKET

FIGURE 3 GLOBAL VAGAL NERVE STIMULATION MARKET, BY APPLICATION, 2019 (%)

FIGURE 4 GLOBAL VAGAL NERVE STIMULATION MARKET, BY PRODUCTS, 2019 & 2027 (USD MILLION)

FIGURE 5 GLOBAL VAGAL NERVE STIMULATION MARKET, BY APPLICATION, 2019 (%)

FIGURE 6 GLOBAL VAGAL NERVE STIMULATION MARKET, BY APPLICATION, 2019 & 2027 (USD MILLION)

FIGURE 7 GLOBAL VAGAL NERVE STIMULATION MARKET, BY END USER, 2019 (%)

FIGURE 8 GLOBAL VAGAL NERVE STIMULATION MARKET, END USER, 2019 & 2027 (USD MILLION)

FIGURE 9 GLOBAL VAGAL NERVE STIMULATION MARKET ANALYSIS, BY REGION

FIGURE 10 GLOBAL VAGAL NERVE STIMULATION MARKET: MARKET STRUCTURE

FIGURE 11 RESEARCH PROCESS OF MRFR

FIGURE 12 DROC ANALYSIS OF GLOBAL VAGAL NERVE STIMULATION MARKET

FIGURE 13 DRIVERS IMPACT ANALYSIS: VAGAL NERVE STIMULATION MARKET

FIGURE 14 RESTRAINTS IMPACT ANALYSIS: VAGAL NERVE STIMULATION MARKET

FIGURE 15 SUPPLY / VALUE CHAIN: GLOBAL VAGAL NERVE STIMULATION MARKET

FIGURE 17 GLOBAL VAGAL NERVE STIMULATION MARKET, BY PRODUCTS, 2019 & 2027 (USD MILLION)

FIGURE 18 GLOBAL VAGAL NERVE STIMULATION MARKET, BY APPLICATION, 2019 & 2027 (USD MILLION)

FIGURE 19 GLOBAL VAGAL NERVE STIMULATION MARKET, BY END USER, 2019 & 2027 (USD MILLION)

FIGURE 20 GLOBAL VAGAL NERVE STIMULATION MARKET SHARE, BY REGION, 2019 (%)

FIGURE 21 GLOBAL VAGAL NERVE STIMULATION MARKET, BY REGION, 2019 & 2027 (USD MILLION)

FIGURE 22 NORTH AMERICA: VAGAL NERVE STIMULATION MARKET SHARE, BY COUNTRY, 2019 (% SHARE)

FIGURE 23 EUROPE: VAGAL NERVE STIMULATION MARKET SHARE, BY COUNTRY, 2019 (% SHARE)

FIGURE 24 ASIA-PACIFIC: VAGAL NERVE STIMULATION MARKET SHARE, BY COUNTRY, 2019 (% SHARE)

FIGURE 25 REST OF THE WORLD: VAGAL NERVE STIMULATION MARKET SHARE, BY REGION, 2019 (% SHARE)

FIGURE 26 GLOBAL VAGAL NERVE STIMULATION MAJOR PLAYERS MARKET SHARE ANALYSIS, 2019 (%)

FIGURE 27 BENCHMARKING OF MAJOR COMPETITORS

FIGURE 28 MAJOR STRATEGY ADOPTED BY KEY PLAYERS IN GLOBAL VAGAL NERVE STIMULATION MARKET

FIGURE 29 SALES & OPERATING INCOME 2019

FIGURE 30 MAJOR PLAYERS R&D EXPENDITURE 2019

FIGURE 31 LIVANOVA PLC: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 32 LIVANOVA PLC: SWOT ANALYSIS

FIGURE 33 RESHAPE LIFESCIENCES, INC: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 34 RESHAPE LIFESCIENCES, INC: SWOT ANALYSIS

FIGURE 35 ELECTROCORE, INC: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 36 ELECTROCORE, INC: SWOT ANALYSIS

FIGURE 37 BOSTON SCIENTIFIC CORPORATION: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 38 BOSTON SCIENTIFIC CORPORATION: SWOT ANALYSIS

FIGURE 39 NEUROMETRIX INC.: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 40 NEUROMETRIX INC.: SWOT ANALYSIS

FIGURE 41 IMTHERA MEDICAL INC.: SWOT ANALYSIS

FIGURE 42 INSPIRE MEDICAL SYSTEMS, INC: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 43 INSPIRE MEDICAL SYSTEMS, INC.: SWOT ANALYSIS

FIGURE 44 PARASYM: SWOT ANALYSIS

FIGURE 45 INNOVATIVE HEALTH SOLUTIONS INC.:SWOT ANALYSIS